Candel therapeutics to present preclinical data at sitc annual meeting showing promise for can-3110 in melanoma, signaling potential indication expansion beyond recurrent high-grade glioma

Needham, mass., nov. 05, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced preclinical results and therapeutic potential of can-3110 in the ras-raf pathway altered melanoma model. the data will be presented at the society for immunotherapy of cancer (sitc) 39th annual meeting, taking place november 6-10, in houston, texas by anne r. diers, phd, senior director of research at candel therapeutics.
CADL Ratings Summary
CADL Quant Ranking